Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adare Acquires Egalet’s Parvulet Technology Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News

Adare Acquires Egalet’s Parvulet Technology Platform

Enhances single-dose formulation of taste-masked, easy-to-swallow oral medications

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adare Pharmaceuticals has entered into an agreement with Egalet Corporation to acquire global rights of the Parvulet technology platform and its associated intellectual property (IP). The technology is protected by several patents granted in the U.S., Canada and Europe with patent life ranging from five to 10 years.
 
Using commonly used pharmaceutical excipients, the technology enables single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pediatric and geriatric populations—including those with dysphagia. One of the unique features of the technology is its ability to enable high dose regimens that may not be feasible by other means, according to the company. Parvulet technology will be complementary to the existing proprietary technologies owned by Adare Pharmaceuticals, allowing the company to expand its product development capabilities.
 
“We are excited to bring this new technology into our portfolio of proven product development technology platforms,” said Ajay Damani, vice president, pharmaceutical technologies, Adare. “It demonstrates our commitment to advancing novel technologies for improved drug delivery mechanisms and better healthcare solutions for patients.”
 
Under the agreement, Egalet will transfer the IP and know-how to Adare Pharmaceuticals, effective immediately. Details of the agreement terms were not disclosed.
 
“Given our focus on our seven commercial products, we are pleased to have signed this agreement enabling Adare to leverage the Parvulet technology to develop new products,” said Mark Strobeck, chief operating officer, Egalet.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics